Innovative thinking to add aesthetic value to the animated logo

From a mental point of view, movement is an essential part of art and it is one of the main sources of expression, the movement is considered part of the nature of life, movement is its essence and time is the core of movement and the measure of life. Animation is one of the artistic works, which is considered a functional goal, the purpose of which is to move the eye over it and to control every artwork to produce a relationship between movement and other elements of art. Movement has laws that push us to show its features. Movement in design is subject to a fixed law, i.e. a law related to the laws of life. Therefore, the designer must struggle to create movement in the design, so we can realize certain unstable conditions and realize that change may be near. The eye always moves in the visual field through paragraphs where it stands short or long depending on the attention it attracts, and the eye can follow a system and rate of its own and can decide exactly whether the line tends in its movement up or down.Innovative thought is achieved in moving the logo through creative thought or acquired because it is a mental process controlled by the mind in one crucible through experience and making sketches and eventually reaching the new movement to attract the attention of the recipient during his vision and achieve the aesthetic value of the logo. All innovations and inventions in human history came through continuous and careful thinking to reach the innovative thought and achieve its aesthetic value. The movement in design may include two ideas: change and time, this change in the visual or mental field may occur in the process of perception of moving logos that serve companies better, so the development of these logos may occur in different forms and patterns, thus achieving aesthetic value

The effectiveness of using the animation technique in building the mental image of the logo

Animation relied in the beginning on the technical creative development to reach forms in which movement flows through optical deception to give a sense of the third dimension and move it at different speeds in order to reach a mental and visual persuasion for the audience until it accepts a movement that did not happen in reality or if it never existed but is purely a fantasy The designer. This technology has accompanied the development of computer graphics and the modern technological renaissance, so designers are using this technology with the latest interactive technological methods in moving logos, which depend on rules and stages with the aim of building a mental image of the recipient by achieving interaction between him and the animated logo, which increases its attractiveness when seeing it. The mental image that the individual forms when he sees the logo of any institution is nothing but a coherent building.It builds a set of ideas and information that the individual stores and preserves the most important characteristics to evoke them when needed. Movement in the logo aims to transform its shape, colour, movement, and others, and a certain aspect of the logo may change, such as: The direction of the icon, the position of the colours, or the entire design gets an overhaul every time the logo is presented so that the movement of the logo stands out, creating an interaction between it and the recipient. The animated logo plays a great interactive role in the formation of the mental image in social media ads and external advertisements and confirming the mental image of the announced institution, through the use of the same logo and the introduction of some influences and dimensions on it to reach the basic form after generating the studied dramatic movement of the animated logo to reach the maximum levels of persuasion for the recipient. The mind cannot keep everything it is exposed to fully all the time, but it retains symbols, images and impressions of objective reality and merely

Titrated Misoprostol Versus Dinoprostone for Labor Induction

Background: Misoprostol is as effective as dinoprostone for labor induction with low cost and temperature stability.Aim: This study designed to compare titrated misoprostol regarding its safety and efficacy with dinoprostone for induction of labor.Subjects and Methods: Women with a single pregnancy, above 37 weeks’ gestation, cephalic presentation, modified Bishop’s score <8, and not in labor with reassuring fetal heart rate, admitted for labor induction enrolled in this randomized controlled study. Studied women were randomized into; Group I: received oral misoprostol titrated in sterile water (200 μg tablet was dissolved in 200 ml sterile water [1 μg/ml]), starting dose of 20 μg misoprostol required, given every 2 h, and stopped if adequate contractions obtained and Group II: received vaginal dinoprostone tablet maximum two doses followed by augmentation of labor by oxytocin ± amniotomy if there is no uterine contractions after two doses of dinoprostone. In Group I, if the contractions were inadequate after two doses of oral titrated misoprostol (20 μg [20 ml]), the starting dose increased to 40 μg (40 ml), escalating the dose from 5 to 10 ml (45–50 μg), and 20 ml (60 μg) maximum ± amniotomy. If the uterine contractions were adequate, the next dose of misoprostol or dinoprostone was omitted. Statistical analysis done using Student’s t‑test for quantitative data and Chi‑square test for qualitative data.Results: Induction‑to‑delivery time was significantly longer in misoprostol than dinoprostone group (975 vs. 670 min, respectively), (P = 0.01). About 20.2% (21/104) of women in misoprostol group did not deliver vaginally within 24 h compared to 7.4% (8/108) in dinoprostone group (significant difference, P = 0.01). Augmentation of labor was significantly high in dinoprostone (37.96% [41/108]) compared to misoprostol group (10.6% [11/104]) (P < 0.01).Conclusion: Titrated misoprostol for induction of labor seems to be associated with significantly longer induction‑to‑delivery time, low incidence of vaginal birth within 24 h, and less need for augmentation of labor compared to vaginal dinoprostone.KEY WORDS: Dinoprostone, labor induction, titrated misoprosto

Sensitive and quantitative detection of Cardiac Troponin I with upconverting nanoparticle lateral flow test with minimized interference

Measurement of cardiac troponin I (cTnI) should be feasible for point-of-care testing (POCT) to diagnose acute myocardial infarction (AMI). Lateral flow immunoassays (LFIAs) have been long implemented in POCT and clinical settings. However, sensitivity, matrix effect and quantitation in lateral flow immunoassays (LFIAs) have been major limiting factors. The performance of LFIAs can be improved with upconverting nanoparticle (UCNP) reporters. Here we report a new methodological approach to quantify cTnI using UCNP-LFIA technology with minimized plasma interference. The performance of the developed UCNP-LFIA was evaluated using clinical plasma samples (n = 262). The developed UCNP-LFIA was compared to two reference assays, the Siemens Advia Centaur assay and an in-house well-based cTnI assay. By introducing an anti-IgM scrub line and dried EDTA in the LFIA strip, the detection of cTnI in plasma samples was fully recovered. The UCNP-LFIA was able to quantify cTnI concentrations in patient samples within the range of 30–10,000 ng/L. The LoB and LoD of the UCNP-LFIA were 8.4 ng/L and 30 ng/L. The method comparisons showed good correlation (Spearman’s correlation 0.956 and 0.949, p </p

Double-Antigen Lateral Flow Immunoassay for the Detection of Anti-HIV-1 and -2 Antibodies Using Upconverting Nanoparticle Reporters

Rapid diagnostic tests (RDTs) are often used for the detection of anti-human immunodeficiency virus (HIV) antibodies in remote locations in low- and middle-income countries (LMIC) with low or limited access to central laboratories. The typical format of an RDT is a lateral flow assay (LFA) with visual interpretation prone to subjectivity. This risk of misinterpretation can be overcome with luminescent upconverting nanoparticle reporters (UCNPs) measured with a miniaturized easy-to-use reader instrument. An LFA with UCNPs for anti-HIV-1/2 antibodies was developed and the assay performance was evaluated extensively with challenging patient sample panels. Sensitivity (n = 145) of the UCNP-LFA was 96.6% (95% CI: 92.1–98.8%) and specificity (n = 309) was 98.7% (95% CI: 96.7–99.7%). Another set of samples (n = 200) was used for a comparison between the UCNP-LFA and a conventional visual RDT. In this comparison, the sensitivities for HIV-1 were 96.4% (95% CI: 89.8–99.3%) and 97.6% (95% CI: 91.6–99.7%), for the UCNP-LFA and conventional RDT, respectively. The specificity was 100% (95% CI: 96.4–100%) for both assays. The developed UCNP-LFA demonstrates the applicability of UCNPs for the detection of anti-HIV antibodies. The signal measurement is done by a reader instrument, which may facilitate automated result interpretation, archiving and transfer of data from de-centralized locations.</p

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30 min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers.</p

Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias

Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids, or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer's disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluid-based biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluid-based biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective

Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias

Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer\xe2\x80\x99s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluid-based biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluid-based biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective

Detection of antibodies to the hepatitis C virus using up-converting nanoparticles-based lateral flow immunoassay

Hepatitis C virus (HCV), an RNA virus, causes acute hepatitis and frequently causes chronic hepatitis, which can lead to liver cirrhosis and primary liver cancer. In 2015, the WHO reported that HCV infection globally affects 71 million persons, accounting for 1% of the population. Nonetheless, among them, only 20% (14 million) were diagnosed. The majority of HCV diagnostic tests are performed in large-scale centralized laboratories; the available tests need high operational costs and trained personnel. There is a pressing need for simple, affordable; quality assured HCV diagnostic test for decentralized and resource-constrained settings. In order to develop the lateral flow immunoassay (LFIA) strips, a physical mixture of recombinant (r) HCV multiepitope protein (rHCV-MEP; containing peptides from structural and non-structural proteins of HCV) and rHCVNS3-core (a fusion of non-structural protein 3 (NS3) and core protein of HCV) was used as capture antigen on the test line of anti-HCV LFIA strips. Recombinant Protein-A conjugated to upconverting nanoparticles (UCNPs) was used as a tracer. The assay was optimized using the model analyte (anti-HCV-MEP rabbit serum) spiked in goat and human serum. A reliable LFIA based on (UCNPs) as the label was developed for the qualitative detection of anti-HCV antibodies in human serum. The developed LFIA was evaluated with 50 anti-HCV positive and 50 anti-HCV negative human serum samples. The LFIA detected anti-HCV antibodies with a sensitivity of 92% (95% CI: 80.77% to 97.78%) and a specificity of 100% (95% CI: 92.89% to 100.00%). The assay could be optimized further to be used as a rapid point-of-care assay in the emergency units, physicians’ clinics, decentralized laboratories, and resource-constrained settings

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30 min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers